Mayne Pharma Group (MYX) Stock Price, News & Analysis

Company Overview

Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally. The company operates through four segments: International Branded Products, and Portfolio Product Division. It provides oral drug delivery systems; and contract development and manufacturing services to third-party customers, as well as distributes specialty pharmaceutical products in the dermatology, women's health, and infectious disease therapeutic areas. The company was formerly known as Halcygen Pharmaceuticals Limited and changed its name to Mayne Pharma Group Limited in November 2010. Mayne Pharma Group Limited was incorporated in 2005 and is based in Salisbury South, Australia.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 5.47 million shs
• Average Volume: N/A
• Market Capitalization: A$446.85 million
• P/E Ratio: N/A
• Dividend Yield: 0.84%
• Price Target: N/A
• Consensus Rating: N/A

MYX Stock Analysis - Frequently Asked Questions

How were Mayne Pharma Group's earnings last quarter?

Mayne Pharma Group Limited (ASX:MYX) announced its quarterly earnings results on Friday, February, 22nd. The company reported $0.02 earnings per share for the quarter. Mayne Pharma Group had a negative trailing twelve-month return on equity of 34.78% and a negative net margin of 44.86%.

What other stocks do shareholders of Mayne Pharma Group own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Mayne Pharma Group investors own include Appen (APX), Aurora Cannabis (ACB), Sundance Energy (SNDE), Turquoise Hill Resources (TRQ), Pilbara Minerals (PILBF), Organigram Global (OGI) and Karoon Energy (KAR).

Company Calendar

• Last Earnings: 2/22/2019
• Today: 6/30/2025

Industry, Sector and Symbol

• Stock Exchange: ASX
• Sector: Medical
• Industry: Drug Manufacturers - General
• Sub-Industry: N/A
• Current Symbol: ASX:MYX
• CIK: N/A
• Web: www.maynepharma.com
• Phone: +61-8-82092666
• Fax: N/A
• Employees: 780
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): A($2.19)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: 0.51
• Net Income: -A$168.62 million
• Net Margins: -44.86%
• Pretax Margin: N/A
• Return on Equity: -34.78%
• Return on Assets: -2.33%

Debt

• Debt-to-Equity Ratio: 8.55
• Current Ratio: 1.47
• Quick Ratio: 0.62

Sales & Book Value

• Annual Sales: A$388.40 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 7.20
• Book Value: A$5.59 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 85,070,000
• Free Float: N/A
• Market Cap: A$446.85 million
• Optionable: Not Optionable
• Beta: 1.24